Key result
Digitoxin reduces HF hospitalization or death by ~18% versus placebo in HFrEF.
RCT (n=1,212)
Double-blind
Randomized
Yes
Answers are grounded in this paper and cite their sources.
Shows favorable win ratios for digitoxin over placebo in heart failure with reduced ejection fraction, indicating robust clinical benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted an RCT in Advanced chronic heart failure with reduced ejection fraction (n=1,212). Digitoxin vs. Placebo was evaluated on Time to first heart failure hospitalization (HFH) or all-cause death (HR 0.82, 95% CI 0.69–0.98, p=0.0268). Digitoxin improved outcomes over placebo for first HF hospitalization or death and prioritized win ratio in HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: